Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 295

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 295
---
 by us include obligations to pay royalties for sales of ELYXYB in the ELYXYB Territory for all indications and additional amounts if
certain net sales and regulatory milestones are achieved.

Romeg License and Commercialization Agreement

On the Original Signing Date, we entered into the Romeg License Agreement with Romeg, which agreement was subsequently amended on
January 16, 2025.

Under the Romeg License Agreement, among other things, Romeg granted us (1) a license, with the right to
sublicense, under the patents and know-how specified therein to (a) commercialize the Initial Licensed Product in the Romeg U.S. Territory, (b) develop other products comprising the Initial Licensed
Product as an active pharmaceutical ingredient and commercialize any such products in the Romeg U.S. Territory and (c) manufacture Licensed Products anywhere in the world, solely for commercialization in the Romeg U.S. Territory; (2) an
exclusive license, with right to sublicense, to use the Licensed Trademark in connection with the commercialization of the Initial Licensed Product solely in the Romeg U.S. Territory; and (3) pursuant to the amendment thereto, a license, with
the right to (a) sublicense under the know-how and, if any, patents existing worldwide in the Romeg Ex-U.S. Territory, as specified therein, to develop, manufacture
and commercialize Licensed Products in the Romeg Ex-U.S. Territory and (b) to use the Licensed Trademark in connection with the commercialization of the Licensed Products in the Romeg Ex-U.S. Territory. With respect to the foregoing clause (1), the license to know-how is exclusive for purposes of developing and commercializing Licensed Products in the Romeg
U.S. Territory during the Romeg U.S. Territory Royalty Term, but is otherwise non-exclusive, and the license to patents is exclusive for purposes of developing and commercializing Licensed Products in the
Romeg U.S. Territory until July 1, 2027 and, thereafter, is co-exclusive with Granules Pharmaceuticals, Inc. for the Romeg U.S. Territory Royalty Term for such purposes. The Romeg U.S. Territory Royalty
Term begins on the Original Signing Date and ends on the later of (i) expiration of the last to expire of the patents that covers the manufacture or commercialization of the Licensed Products in the Romeg U.S. Territory or (ii) the tenth
anniversary of the